

EXTRAORDINARY GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Incorporated in the People's Republic of China)

(Company Registration No.: 91120000103100784F)

(the “Company”)

NOTICE OF EXTRAORDINARY GENERAL MEETING

IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS

This Notice of Extraordinary General Meeting has been given in accordance with the notice period prescribed under applicable PRC law.

The Company will issue an updated Notice of Extraordinary General Meeting 14 days before the Extraordinary General Meeting, in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide S-Share Shareholders with details of the arrangements for participating in the Extraordinary General Meeting in Singapore. S-Share Shareholders should check SGXNet for the latest updates on the status of the Extraordinary General Meeting.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (“**EGM**” or “**Extraordinary General Meeting**”) of the Company will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China (the “**PRC**”) 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for holders of the S-Shares (“**S-Share Shareholders**”) in Singapore) on Friday, 31 July 2026 at 2:00 p.m..

To consider and, if thought fit, approve the following resolutions, with or without modifications:

Resolution 1: To consider and approve the proposed adoption of the remuneration policy for directors and senior management (《董事、高级管理人员薪酬管理制度》); and

Resolution 2: To consider and approve the directors' remuneration proposal for 2026 (《2026 年度董事薪酬方案》).

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
15 July 2026

Notes:

1. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 31 July 2026 at 2:00 p.m..

As mentioned above, the Company will issue an updated Notice of EGM 14 days before the EGM, in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide S-Share Shareholders with details of the arrangements for participating in the EGM in Singapore. S-Share Shareholders should check SGXNet for the latest updates on the status of the EGM.

2. A Shareholder (whether individual or corporate) who is entitled to attend and vote at the EGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointments shall be deemed to be alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

3. The EGM in Tianjin, the PRC is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/her/its proxy(ies) in connection with his/her/its attendance at the EGM shall be borne by that Shareholder.
4. **Personal data privacy:** By (1) submitting a proxy form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the EGM and/or any adjournment thereof, (2) submitting any question prior to the EGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the EGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolution(s) to be tabled for approval at the EGM from Shareholders received prior to and/or at the EGM and if necessary, the follow-up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"); (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), such Shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes; and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.